Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

Senti Biosciences (Nasdaq: SNTI) announced that CEO and co-founder Timothy Lu, M.D., Ph.D. will present at the Leerink Partners 2026 Global Healthcare Conference in Miami on March 9, 2026 at 2:20 PM ET.

Rhea-AI Summary

Senti Biosciences (Nasdaq: SNTI) announced that CEO and co-founder Timothy Lu, M.D., Ph.D. will present at the Leerink Partners 2026 Global Healthcare Conference in Miami on March 9, 2026 at 2:20 PM ET. A live webcast will be available and a replay will be posted on the company’s Investors Events page.

This is a corporate presentation by a clinical-stage company developing cell and gene therapies using its Gene Circuit platform.

Argus Mar 3 session

+2.14% close to close Open Argus

Details

News Market Reaction – SNTI

In the Mar 3 session, SNTI gained 2.14%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Senti Biosciences’ continued engagement with investors via the Leerink ...

Analysis

This announcement highlights Senti Biosciences’ continued engagement with investors via the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026. It reiterates the company’s positioning around its Gene Circuit platform but adds no new clinical, regulatory, or financial data. Investors may focus on upcoming trial milestones, financing developments, and any substantive updates delivered during or after the conference webcast.

Key Figures

Conference date: March 9, 2026 Presentation time: 2:20 PM ET Announcement date: March 03, 2026

Conference date

March 9, 2026

Leerink Partners 2026 Global Healthcare Conference presentation date

Presentation time

2:20 PM ET

Scheduled time for Leerink conference presentation

Announcement date

March 03, 2026

Press release date for Leerink conference participation

Historical Context

5 past events · Latest: Feb 24

5 events

1. Feb 24

   Conference presentation

   24h Move

   +7.1%

   CEO presentation at TD Cowen healthcare conference with webcast access.

2. Feb 20

   Investor event

   24h Move

   -3.4%

   Participation in Cell & Gene Live virtual event on Gene Circuit platform.

3. Feb 11

   Clinical milestone

   24h Move

   -1.9%

   Completion of Phase 1 enrollment for SENTI-202 with supportive ASH data.

4. Feb 03

   Conference presentation

   24h Move

   -3.0%

   On-stage presentation at Healthcare Conference Taipei 2026.

5. Jan 14

   Regulatory/clinical update

   24h Move

   +3.8%

   Virtual CEO segment highlighting RMAT designation and new AML trial data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

gene circuit

1 terms

gene circuit technical

"developing next-generation cell and gene therapies using its proprietary Gene Circuit platform"

A gene circuit is an engineered arrangement of DNA parts and genes that sense signals, process information and produce a specific biological response inside a cell—similar to how an electronic circuit uses wires and components to perform a task, but built from genes and proteins. Investors pay attention because gene circuits are the design foundation for precision medicines, diagnostics and bio-manufacturing; their reliability, predictability and manufacturability influence a product’s effectiveness, regulatory path and commercial potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will present at the Leerink Partners 2026 Global Healthcare Conference in Miami, FL on Monday, March 9, 2026, at 2:20 PM ET.

A webcast replay will be available on the Events page of the Investors section of the Company’s website (sentibio.com).

Interested parties may access the live video webcast here.

About Senti Bio

Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline comprises cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.

Availability of Other Information About Senti Biosciences, Inc.

For more information, please visit the Senti Bio website at www.sentibio.com or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
SNTI@jtcir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Senti Biosciences (SNTI) present at the Leerink Partners 2026 Global Healthcare Conference?

Senti Biosciences will present on March 9, 2026 at 2:20 PM ET. According to the company, CEO Timothy Lu will deliver the presentation in Miami and the session will be available via live webcast for remote investors and analysts.

How can investors watch the SNTI presentation at the March 9, 2026 Leerink conference?

Investors can access a live video webcast of the presentation on the company’s investor site. According to Senti Biosciences, a replay will also be posted on the Events page of the Investors section after the live session.

Who will present for Senti Biosciences (SNTI) at the Leerink Partners 2026 Global Healthcare Conference?

Timothy Lu, M.D., Ph.D., co-founder and CEO, will present on behalf of Senti Biosciences. According to the company, he will discuss corporate updates and the company’s clinical-stage work using its Gene Circuit platform.

What topics is Senti Biosciences (SNTI) expected to cover at the March 9, 2026 presentation?

The presentation will cover corporate and clinical-stage developments related to Senti’s Gene Circuit platform. According to Senti Biosciences, the session is intended to update investors on program progress and company strategy without providing specific financial guidance.

Where will the replay of the Senti Biosciences (SNTI) Leerink 2026 presentation be posted?

A webcast replay will be posted on the Events page of the Investors section at sentibio.com. According to the company, interested parties can view the archived video there following the live presentation on March 9, 2026.